Other amplifications with potential clinical implications in investigation were reported, as MYC in 9 melanomas, where it is an important negative prognostic factor, and EGFR in 1 breast cancer patient, present in up to 78% of triple negative cases associated with a worse prognosis and more aggressive metastases [31,32]. This evidence concerns the gene MYC and melanoma.